A Review of the Data Supporting Use of COVID-19 Vaccinations in the Pediatric Population

Stultz, Jeremy S.; Eiland, Lea S.

doi:10.1177/10600280231156625

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Stultz et al [54] provided a review of relevant safety considerations regarding COVID-19 vaccines in children, either in authorization studies or post-marketing analyses. These observations confirmed that most common adverse effects are mild/moderate, mostly lasting 1 or 2 days, and typically 16% or less of the time have an impact on the ability to perform daily activities (e.g., school attendance).…”

Section: Surveillance Data (Post-authorization Monitoring)mentioning

confidence: 99%

Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review

Mastrolia,

De Cillia,

Orlandi

et al. 2023

Medicina

View full text Add to dashboard Cite

This narrative review aims to report the main clinical manifestations, therapeutic strategies, outcomes, and complications of acute SARS-CoV-2 infection in childhood and to summarize the data relating the SARS-CoV-2 vaccination efficacy and safety in pediatric age. SARS-CoV-2 infection mostly occurs asymptomatically in the pediatric population, while multisystem inflammatory syndrome in children (MIS-C) represents the most severe coronavirus disease 2019 (COVID-19)-related illness, a life-threatening event with a high morbidity rate. After the development of SARS-CoV-2 vaccines and their subsequent approval in children, the rate of infection as well as the number of its related complications have shown a drastic decrease. Fully vaccinated children are protected from the risk of developing a severe disease and a similar protective role has been observed in the reduction of complications, in particular MIS-C. However, long-lasting immunity has not been demonstrated, booster doses have been required, and reinfection has been observed. With regards to vaccine safety, adverse events were generally mild to moderate in all age groups: local adverse events were the most commonly reported. Nevertheless, a potential association between SARS-CoV-2 vaccine and the subsequent development of inflammatory manifestations has been suggested. Myocarditis has rarely been observed following vaccination; it appeared to be more frequent among adolescent males with a mild clinical course leading to a complete recovery. SARS-CoV-2 vaccine-related MIS-C cases have been described, although a univocal definition and an exact time interval with respect to vaccination has not been reported, thus not establishing a direct causal link. Current evidence about COVID-19 vaccination in children and adolescents suggest that benefits outweigh potential risks. Long-term data collection of the post-authorization safety surveillance programs will better define the real incidence of SARS-CoV-2 vaccine-related complications in the pediatric population.

show abstract

Section: Surveillance Data (Post-authorization Monitoring)mentioning

confidence: 99%

Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review

Mastrolia,

De Cillia,

Orlandi

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups

Pourriyahi,

Hajizadeh,

Khosravi

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionThe COVID‐19 pandemic has taken many forms and continues to evolve, now around the Omicron wave, raising concerns over the globe. With COVID‐19 being declared no longer a “public health emergency of international concern (PHEIC),” the COVID pandemic is still far from over, as new Omicron subvariants of interest and concern have risen since January of 2023. Mainly with the XBB.1.5 and XBB.1.16 subvariants, the pandemic is still very much “alive” and “breathing.”MethodsThis review consists of five highly concerning questions about the current state of the COVID Omicron peak. We searched four main online databases to answer the first four questions. For the last one, we performed a systematic review of the literature, with keywords “Omicron,” “Guidelines,” and “Recommendations.”ResultsA total of 31 articles were included. The main symptoms of the current Omicron wave include a characteristically high fever, coughing, conjunctivitis (with itching eyes), sore throat, runny nose, congestion, fatigue, body ache, and headache. The median incubation period of the symptoms is shorter than the previous peaks. Vaccination against COVID can still be considered effective for the new subvariants.ConclusionGuidelines recommend continuation of personal protective measures, third and fourth dose boosters, along with administration of bivalent messenger RNA vaccine boosters. The consensus antiviral treatment is combination therapy using Nirmatrelvir and Ritonavir, and the consensus for pre‐exposure prophylaxis is Tixagevimab and Cilgavimab combination. We hope the present paper raises awareness for the continuing presence of COVID and ways to lower the risks, especially for at‐risk groups.

show abstract

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

García-Rivera,

Puga-Gómez,

Fernández-Castillo

et al. 2025

Vaccine: X

View full text Add to dashboard Cite

A Review of the Data Supporting Use of COVID-19 Vaccinations in the Pediatric Population

Cited by 4 publications

References 28 publications

Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review

Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

Contact Info

Product

Resources

About